Literature DB >> 20601851

HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection.

Benedikt Simon1, Katharina Grabmeier-Pfistershammer, Armin Rieger, Mario Sarcletti, Brigitte Schmied, Elisabeth Puchhammer-Stöckl.   

Abstract

OBJECTIVE: A substantial number of HIV infections worldwide are diagnosed at a late stage of disease. Mortality in late presenters is high, and their treatment is a specific challenge. We have determined the relative proportions of HIV-1 strains of different coreceptor tropism (CRT) in this group of patients and investigated the impact of CRT on progression markers such as CD4 cell counts and viral load, and on the clinical presentation of the patients. DESIGN AND METHODS: Plasma samples from 50 treatment-naive patients with a late HIV diagnosis (CD4 cell counts of <200 cells/microl at the time of diagnosis) were analyzed. HIV strains were sequenced, and for CRT determination, the internet tool geno2pheno[coreceptor] was used, with a 20% false-positive rate as the cutoff. Differences in progression markers, patient characteristics and HIV subtype distribution between the R5-infected and X4/DM-infected patient groups were evaluated statistically.
RESULTS: CRT predictions indicated that 62% of the patients had only R5-tropic strains. CRT was not associated with CD4 cell counts or viral load at the time of diagnosis. Only in very late presenters (CD4 cell counts <50 cells/microl) was there a significant difference in disease stage at the time of presentation, showing that patients with R5 more often were at Centers for Disease Control and Prevention stage C3 compared with those with X4/DM strains (P = 0.04).
CONCLUSION: A substantial number of patients diagnosed at a late stage of HIV-1 infection may be infected exclusively with R5-tropic virus strains, making this specific patient group a possible candidate for coreceptor antagonist treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20601851     DOI: 10.1097/QAD.0b013e32833c93e6

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  10 in total

1.  HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.

Authors:  Cécile Tremblay; Isabelle Hardy; Richard Lalonde; Benoit Trottier; Irina Tsarevsky; Louis-Philippe Vézina; Michel Roger; Mark Wainberg; Jean-Guy Baril
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

2.  Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent.

Authors:  Mariangela Cavarelli; Lara Mainetti; Angela Rosa Pignataro; Alba Bigoloni; Monica Tolazzi; Andrea Galli; Silvia Nozza; Antonella Castagna; Michela Sampaolo; Enzo Boeri; Gabriella Scarlatti
Journal:  AIDS Res Hum Retroviruses       Date:  2014-12       Impact factor: 2.205

Review 3.  CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.

Authors:  Michelle B Kim; Kyle E Giesler; Yesim A Tahirovic; Valarie M Truax; Dennis C Liotta; Lawrence J Wilson
Journal:  Expert Opin Investig Drugs       Date:  2016-12       Impact factor: 6.206

4.  Existence of Replication-Competent Minor Variants with Different Coreceptor Usage in Plasma from HIV-1-Infected Individuals.

Authors:  Yosuke Maeda; Taichiro Takemura; Takayuki Chikata; Takeo Kuwata; Hiromi Terasawa; Riito Fujimoto; Nozomi Kuse; Tomohiro Akahoshi; Hayato Murakoshi; Giang Van Tran; Yu Zhang; Chau Ha Pham; Anh Hong Quynh Pham; Kazuaki Monde; Tomohiro Sawa; Shuzo Matsushita; Trung Vu Nguyen; Kinh Van Nguyen; Futoshi Hasebe; Tetsu Yamashiro; Masafumi Takiguchi
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

5.  Risk of all-cause mortality in HIV infected patients is associated with clinical, immunologic predictors and the CCR5 Δ32 deletion.

Authors:  Milosz Parczewski; Dorota Bander; Magdalena Leszczyszyn-Pynka; Anna Urbanska; Mariusz Kaczmarczyk; Andrzej Ciechanowicz; Anna Boron-Kaczmarska
Journal:  PLoS One       Date:  2011-07-18       Impact factor: 3.240

6.  Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage.

Authors:  Salvatore Dimonte; Fabio Mercurio; Valentina Svicher; Roberta D'Arrigo; Carlo-Federico Perno; Francesca Ceccherini-Silberstein
Journal:  Retrovirology       Date:  2011-05-12       Impact factor: 4.602

7.  The temporal increase in HIV-1 non-R5 tropism frequency among newly diagnosed patients from northern Poland is associated with clustered transmissions.

Authors:  Miłosz Parczewski; Magdalena Leszczyszyn-Pynka; Magdalena Witak-Jędra; Katarzyna Maciejewska; Sławomira Myślińska; Anna Urbańska
Journal:  J Int AIDS Soc       Date:  2015-08-20       Impact factor: 5.396

8.  Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression.

Authors:  Antonella Castagna; Laura Monno; Stefania Carta; Laura Galli; Stefania Carrara; Valentina Fedele; Grazia Punzi; Iuri Fanti; Pietro Caramello; Alessandro Cozzi Lepri; Andrea De Luca; Francesca Ceccherini-Silberstein; Antonella d'Arminio Monforte
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

9.  Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.

Authors:  David Beauparlant; Peter Rusert; Carsten Magnus; Claus Kadelka; Jacqueline Weber; Therese Uhr; Osvaldo Zagordi; Corinna Oberle; Maria J Duenas-Decamp; Paul R Clapham; Karin J Metzner; Huldrych F Günthard; Alexandra Trkola
Journal:  PLoS Pathog       Date:  2017-03-06       Impact factor: 6.823

10.  Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.

Authors:  Matteo Surdo; Emanuela Balestra; Patrizia Saccomandi; Fabiola Di Santo; Marco Montano; Domenico Di Carlo; Loredana Sarmati; Stefano Aquaro; Massimo Andreoni; Valentina Svicher; Carlo Federico Perno; Francesca Ceccherini-Silberstein
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.